TGTX FY 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$329M+40.8% YoY

Gross Profit

$291M88.3% margin

Operating Income

$42M12.7% margin

Net Income

$23M7.1% margin

EPS (Diluted)

$0.15

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$578M

Total Liabilities

$355M

Stockholders' Equity

$222M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$329M	$234M	+40.8%
Gross Profit	$291M	$220M	+32.3%
Operating Income	$42M	$21M	+103.2%
Net Income	$23M	$13M	+84.5%